Enzo Biochem, Inc.

As of June 9, 2022, Enzo Biochem, Inc. is considered overvalued and risky due to its negative financial metrics, including a Price to Book Value of 0.67, an EV to EBITDA ratio of 1.12, and poor stock performance compared to the S&P 500, with a YTD return of -2.16% and a 5Y return of -70.39%.

As of April 23, 2025, the market trend is mildly bearish, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, but overall sentiment remains weak compared to the S&P 500.

As of June 9, 2022, Enzo Biochem, Inc. is considered overvalued with a valuation grade of risky, reflected by key financial metrics such as a Price to Book Value of 0.67, an EV to EBITDA of 1.12, a negative ROE of -12.03%, and a year-to-date stock decline of 25.48% compared to a 2.44% gain for the S&P 500.

As of March 2022, the management team of Enzo Biochem, Inc. includes Dr. Elazar Rabbani as Chairman and CEO, with Mr. Dov Perlysky as Lead Independent Director and independent directors Dr. Rebecca Fischer, Dr. Mary Tagliaferri, and Dr. Ian Walters.

Enzo Biochem, Inc. is a micro-cap bioscience company that develops products and services in the Pharmaceuticals & Biotechnology sector. As of January 2025, it reported net sales of $7 million and a net loss of $1 million, with a market cap of $28.30 million.

As of Jun 18, Enzo Biochem, Inc. has a market capitalization of 28.30 million, with net sales of 29.09 million and a net profit of -7.60 million over the last four quarters. The company's shareholder's funds are 56.11 million, and total assets are 85.76 million as of Jul 24.